Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia
Status:
Recruiting
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
This single-center, prospective, open-label, comparator study, blind for central accessor
evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with
pneumonia with confirmed or suspected COVID-19. All patients will receive 0,1 mg of melphalan
in 7-10 daily inhalations 1 time per day.
Phase:
Phase 2
Details
Lead Sponsor:
Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Collaborators:
Medsi Clinic #1, Moscow Moscow State University of Medicine and Dentistry